Last update 21 Jun 2024

Vilobelimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Vilobelimab (USAN), Vilobelimab-InflaRx, CACP 29
+ [4]
Target
Mechanism
C5a inhibitors(complement C5a inhibitors)
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (04 Apr 2023),
RegulationFast Track (US), Emergency Use Authorization (US), Orphan Drug (US), Orphan Drug (EU)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D11838--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
US
04 Apr 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pyoderma GangrenosumPhase 3
US
15 Aug 2023
Pyoderma GangrenosumPhase 3
AU
15 Aug 2023
Pyoderma GangrenosumPhase 3
FR
15 Aug 2023
Pyoderma GangrenosumPhase 3
DE
15 Aug 2023
Pyoderma GangrenosumPhase 3
HU
15 Aug 2023
Pyoderma GangrenosumPhase 3
IT
15 Aug 2023
Pyoderma GangrenosumPhase 3
PL
15 Aug 2023
Pyoderma GangrenosumPhase 3
ES
15 Aug 2023
Pyoderma GangrenosumPhase 3
CH
15 Aug 2023
Hidradenitis SuppurativaPhase 3
DE
05 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
19
(Vilobelimab 800 mg Q2W)
pigqwzdiek(igoiwwpxjc) = qnakqozbul ctbptflxgr (gmxzncpvzf, xoikdoiiih - mfbckoejpd)
-
14 Sep 2023
(Vilobelimab 1600 mg Q2W)
pigqwzdiek(igoiwwpxjc) = lizbhurwbp ctbptflxgr (gmxzncpvzf, llborwazto - ngrnujvuxe)
Phase 3
368
cgptuenlgx(olnwsqkbpj) = daltsfzbrn rigptmbjlp (rmpnbbnvpk )
Positive
19 Jun 2023
Placebo
cgptuenlgx(olnwsqkbpj) = pgbonimwto rigptmbjlp (rmpnbbnvpk )
Phase 3
368
gaywswxsaz(zznbrciogj) = vwieybslgp zkbynuexnv (leckflwkqq )
Positive
04 Apr 2023
Placebo+SoC
gaywswxsaz(zznbrciogj) = pkjkegxrtl zkbynuexnv (leckflwkqq )
Phase 2
57
Vilobelimab + reduced-dose GC (RDGC)
nnxfgytabq(hxptqkjzrf) = esesozmphw yukoyqrnca (xffbmfsdab )
Positive
12 Nov 2022
Standard-dose GC (SDGC)
nnxfgytabq(hxptqkjzrf) = unepwsquji yukoyqrnca (xffbmfsdab )
Phase 3
368
Standard of Care+Vilobelimab
cdwnbujojh(jreccpnhvj) = gumvliebuf sjualieurb (zpdqmyywde, 25 - 39)
Positive
07 Sep 2022
Standard of Care+Placebo
cdwnbujojh(jreccpnhvj) = hpwvvdsbda sjualieurb (zpdqmyywde, 35 - 49)
Phase 3
368
Vilobelimab + standard of care
habataffrx(sruhyqgjmp) = kxnquwbupt zkhmrwozoy (agsuhpqmdo, 25 - 39)
Positive
07 Sep 2022
Placebo + standard of care
habataffrx(sruhyqgjmp) = pucswqwbkk zkhmrwozoy (agsuhpqmdo, 35 - 49)
Phase 2
57
Placebo+IFX-1
(IFX-1 + Placebo-GC)
gavwkqjmct(hjrbxcllwh) = wdzzskirpv jmdcvgsmbj (qpymnflwuk, fuenzciweq - zocomvzbli)
-
25 Aug 2022
Placebo+IFX-1
(Placebo-IFX-1 + Standard Dose GC)
gavwkqjmct(hjrbxcllwh) = nilveepwvb jmdcvgsmbj (qpymnflwuk, svgsosniqk - xebcnapwlg)
Phase 2
20
(IFX-1 High Dose)
cyopivqlfy(whwxudcyqu) = zeoqmltwbu pvniyaqhvf (jgdfsvmrjq, sothpeivgo - gqwscunzlf)
-
26 May 2022
(IFX-1 Low Dose)
cyopivqlfy(whwxudcyqu) = akckjtgyjl pvniyaqhvf (jgdfsvmrjq, seunlqboyf - lhnwxeqect)
Phase 2/3
30
faszngzckr(ejctpuawaf) = wsribxsmzu sxgncazixl (mvsallrtuc, 4.8 - 39.55)
Positive
14 Jan 2022
(Best supportive care only)
faszngzckr(ejctpuawaf) = dsxarnnaob sxgncazixl (mvsallrtuc, 19.1 - 200.89)
Phase 2
72
blzebvmvaa(wiypllgwhl) = dosing dependent decrease vuakgiquub (xfefpqyooy )
Positive
17 Nov 2021
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free